Lyophilized Resiniferatoxin Composition for Stable Low-Dose Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions containing Resiniferatoxin for treating knee joint pain, particularly osteoarthritic knee joint pain, are not satisfactory in terms of storage stability, shelf-life, ease of application, and safety, especially at low doses, and often result in undesirable side effects.
Innovation Solution
A reconstitutable solid pharmaceutical composition comprising Resiniferatoxin in amounts less than 3.20 μg, preferably at most 900 ng, with a surfactant like TPGS and optionally a buffer, stored as a lyophilizate, which is reconstituted with an ethanol-containing liquid for intraarticular administration, providing improved storage stability and enhanced tissue distribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If Resiniferatoxin is formulated in liquid form for intraarticular injection, then ease of administration is improved, but storage stability and shelf-life deteriorate
Solution Approach 1:
The pharmaceutical composition is divided into two separate components: a lyophilized solid residue containing Resiniferatoxin and excipients, and a reconstitution liquid. This segmentation allows the drug to be stored in a stable solid form and only converted to liquid form immediately before administration, resolving the contradiction between storage stability and ease of administration.
Solution Approach 2:
The Resiniferatoxin is pre-formulated into a lyophilized solid residue with appropriate excipients (surfactant, buffer, stabilizer) before storage. This preliminary preparation ensures optimal storage stability and shelf-life, while the actual liquid formulation occurs only when needed through reconstitution with the provided liquid, maintaining both stability during storage and ease of use at administration time.
2Reliability
If high doses of Resiniferatoxin are used for pain treatment, then therapeutic efficacy is improved, but adverse side effects increase
Solution Approach 1:
The formulation enables precise control of Resiniferatoxin dosage through the lyophilized solid residue containing a specific amount of active ingredient (e.g., 100-500 mcg). By changing the formulation parameters during manufacturing, exact therapeutic doses can be achieved without exceeding safe limits, thereby maintaining efficacy while minimizing adverse effects. The controlled release properties of the lyophilized form also contribute to sustained therapeutic action at lower peak concentrations.
Solution Approach 2:
Excipients such as surfactants (TPGS), buffers, and stabilizers act as intermediaries that enhance the therapeutic efficacy of Resiniferatoxin while reducing its adverse effects. These substances improve drug solubility, stability, and tissue distribution, allowing lower doses to achieve the same therapeutic effect, thereby reducing toxicity while maintaining reliability.
3Stability of the object's composition
If Resiniferatoxin is stored at low temperatures to maintain stability, then storage stability is improved, but manufacturing and distribution complexity increase
Solution Approach 1:
The Resiniferatoxin is formulated and lyophilized into a solid residue that is stable at room temperature. The phase transition from liquid to solid through lyophilization removes the need for cold chain storage and transportation. The solid lyophilized form maintains stability without requiring refrigeration, significantly simplifying manufacturing and distribution logistics while preserving storage stability.
4Ease of operation
If fast reconstitution is achieved by adding liquid to the solid composition, then ease of administration is improved, but reconstitution time may be insufficient for complete dissolution
Solution Approach 1:
The reconstitution process utilizes hydraulic principles by adding a specific volume of reconstitution liquid to the lyophilized solid residue. The liquid rapidly penetrates and dissolves the solid matrix through capillary action and diffusion, achieving complete reconstitution within a short, predictable time frame. This controlled hydraulic approach ensures both speed and completeness of dissolution, resolving the contradiction between fast reconstitution and complete dissolution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition offers satisfactory storage stability at room temperature, improved reconstitution times, reduced adverse events, and prolonged pain relief of several months with ultra-low doses of Resiniferatoxin, making it suitable for long-term treatment.
Implementation Method 1
stored as a lyophilizate
Data Source
AI summary
The invention relates to a reconstitutable solid pharmaceutical composition comprising or essentially consisting of Resiniferatoxin in an amount of less than 3.20 μg, preferably at most 900 ng, more preferably at most 500 ng; optionally, a surfactant; and optionally, a buffer. The composition according to the invention is particularly useful for the treatment of pain due to knee osteoarthritis. Prior to administration, the solid composition is reconstituted with a reconstitution liquid thereby obtaining a reconstituted composition. Said reconstituted composition or a partial volume thereof is subsequently administered as dose unit, preferably by intraarticular injection into the knee.